Kornimate/medical-research-clean huggingface dataset:
internet based cognitive behavior treatment for alcohol problems

Conditions: Alcohol Use Disorders

Summary: the purpose of this study is to determine whether internet based cognitive behavior therapy might be effective in the treatment of alcohol problems.

a 12 week internet based self help program based on cognitive behavioral therapy and relapse prevention is tested among internet help seekers as well as among patients seeking help in addiction care.the design is a one armed pilot study, and outcomes are measured in terms of changes in alcohol consumption, problematic alcohol use, self efficacy, craving, as well as depression and quality of life. 20 participants are recruited entirely online from an open access website and 20 participants are recruited through information given to them at an addiction clinic. all participants have access to the same self help program and have access to a licensed psychologist who guides the person all the way through the program.

Eligibility criteria:
inclusion criteria: * ≥ 18 years * access to the internet * problematic alcohol use defined as ≥ 16 p or more for men and ≥ 14 p or more for women in the alcohol use identification scale exclusion criteria: * not adequately fluent in swedish * reading or writing impairment if this is so severe as to affect treatment * ongoing psychological treatment with content similar to the treatment being studied * suicide risk defined as ≥ 4 p på madrs-s q 9 or through a telephone interview with clinician * severe depression defined as madrs-s ≥ 30 p * somatic or psychiatric conditions that are contraindicated for the treatment such as psychosis, bipolar disorder (depressive or manic phase), severe post traumatic stress disorder. * has during the last 3 weeks begun using medication for alcohol problems or other psychiatric disorder

Keywords: alcohol use disorder internet cognitive behavior therapy relapse prevention
a study comparing the effect of atomoxetine versus other standard care therapy on the long term functioning in attention-deficit/hyperactivity disorder (adhd) children and adolescents

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this study is to demonstrate that atomoxetine is superior to other early standard therapy (any treatment that investigator considers is appropriate to initiate for the treatment of attention-deficit/hyperactivity disorder \[adhd\]) on the long term functioning in approximately 400 children and adolescents with adhd. patients will be pharmacological naïve prior to entry into the study.


Eligibility criteria:
inclusion criteria: * inclusion criteria: * 6 to 16 years old * diagnosis of adhd according to diagnostic and statistical manual of mental disorders fourth edition (dsm iv) confirmed by kiddie schedule for affective disorders and schizophrenia for school aged children-present and lifetime version (sads pl) * pharmacological naïve * normal intelligence as assessed by investigator * each patient (and/or legally authorized patient representative where required by local law) must understand the nature of the study and must sign an informed consent document. exclusion criteria: * exclusion criteria * history of bipolar disorder, any history of psychosis or autism spectrum disorder * history of any seizure disorder * significant prior or current medical conditions * history of alcohol or drug abuse within the past 3 months * patients who are taking concurrently any of the excluded medications in the study.
evaluation of functional improvement after spa therapy in fontcaude center

Conditions: Knee Osteoarthritis

Summary: evaluation of functional improvement after spa therapy in fontcaude center, for knee osteoarthritis background. knee osteoarthritis is the first indication of spa therapy in rheumatology. this therapeutic represents a non pharmacological treatment and is recommended by oarsi. in order to obtain agreement for spa therapy, the center fontcaude, needs to show clinical improvement for patients, as demonstrated in the thermarthrose study. this center is near montpellier and could improve patients localised in this area.

methods: randomised prospective clinical trial of patients with knee osteoarthritis. the spa therapy group received 18 days of therapy over 3 weeks. patients in the control group received 18 days of therapy over 3 weeks after the 6-month follow-up visit. follow-up was at 3 and 6 months, by a visit to the examination. the hypothesis of our study is to demonstrate clinical improvement at six months. the main endpoint is the number of patients achieving minimal clinically important improvement (mcii) at 6 months, defi ned as ≥19.9 mm on the visual analogue pain scale and/or ≥9.1 points in a normalised western ontario and mcmaster universities osteoarthritis index function score.

Eligibility criteria:
inclusion criteria: * patient aged 40 to 75 years with radiologic and gonarthrosis radiologic et painful gonarthrosis, unilateral ou bilateral, whatever is the radiographic stage * patient presenting a eva ≥3 with a corresponding radiology at least of 1year * patient affiliated with a social security system exclusion criteria: * realization of a water cure in the last 6 months * infiltration of the knee of less than 3 months * impossibility to sign the informed consent or which for reasons geographical, social or psychological could not be regularly followed, * person major placed under guardianship or trusteeship, * private person of freedom by court or administrative order, nobody being the object of a legal protective measure, * patient already included in an interventional clinical protocol, * pregnant women * contraindication in the water cure: * severe change of the general state or debilitating afflictions * acute affections and pushed acute(sharp) of the chronic affections * grave cardiac insufficiency, unstable arterial high blood pressure * severe renal or hepatic insufficiency * not healed cutaneous hurts * contagious or evolutionary diseases * evolutionary cancers * current immunomodulator or immunosupressor treatment, waves of inflammation.
use of pain medication following periodontal procedures

Conditions: Periodontal Diseases; Pain

Summary: this study had the following aims: i. to determine the relationship between anticipated pain and actual pain experienced following periodontal surgery; and ii. determine the factors that predict the amount of pain and the amount of pain medication use following periodontal surgery. it was hypothesized that experienced pain will be significantly less than anticipated pain. it was also hypothesized that the following factors will affect pain experienced: sex, type of surgery, nervousness, anticipated pain, sedation, age, smoking status, supplement use and pain pill usage. it was hypothesized that the following factors will affect pain pill usage: sex, type of surgery, nervousness, anticipated pain, sedation, age, smoking status, supplement use, and actual pain.

patients may delay or avoid periodontal procedures because of fear of dental pain they will experience. by understanding factors that influence pain experienced, practitioners can provide potentially provide accommodations for their patients. this study investigated if anticipated pain is similar to actual pain experienced and if there are certain factors that influence the amount of pain experienced and/or pain pill usage. patients kept a 7 day diary in which they recorded anticipated pain (prior to periodontal surgery) and actual pain experienced for 7 days following the surgical procedure. patients recorded their pain (anticipated and actual) using a visual analog scale (vas). patients also recorded daily pain medication and nutritional supplement use in the 7 day diary. other information recorded included factors that could influence pain experienced and pain pill use. for pain experienced, the influence of the following factors were assessed: sex, age, type of surgery, nervousness, sedation use, smoking status, anticipated pain, nutritional supplement use and pain pill use. for pain pill use, the influence of the following factors were assessed: sex, age, type of surgery, nervousness, sedation use, smoking status, anticipated pain, nutritional supplement use and pain experienced. these factors were analyzed using regression analyses.

Eligibility criteria:
inclusion criteria: * require dental implant surgery or soft tissue graft surgery exclusion criteria: * regularly took pain medication for pre-existing health conditions * previous implant or soft tissue graft surgery

Keywords: periodontal therapy anticipated pain experienced pain pain medication use
effects of pilates exercises versus pelvic floor muscle exercises among elderly women with urinary incontinence

Conditions: Urinary Incontinence

Summary: to compare the effects of pilates exercises versus pelvic floor muscle exercises among elderly women with urinary incontinence. the study is a single-blinded randomized clinical trial. 70 patients(calculated through pass version 15 software) will be selected. subjects will be screened whether they met inclusion and exclusion criteria. the participants for this study will be elderly women with urinary incontinence. the participants will be recruited from sipmr and civil hospital karachi. the initial assessment will be done by medical consultant. patients must fulfill inclusion criteria. consent must be taken from each patient and samples will be collected in the given time frame and patients will be randomly assigned(through a randomization sheet) to the treatment groups. treatment group 1 will be doing pilates exercises and treatment group 2 will be doing pelvic floor muscle exercises. ems will be given to both treatment groups. a voiding diary, stamey's urinary incontinence system, and iqol questionnaire will be used at baseline assessment and at the end of treatment sessions. 12 treatment sessions will be given, 3 visits each week for 4 weeks. the data will be analyzed on spss version 21. : non-probability purposive sampling technique will be used for selecting individuals. percentages and frequencies will be calculated for categorical variables and parametric and nonparametric tests will be applied.


Eligibility criteria:
inclusion criteria: * elderly females from an outpatient setting of sindh institute of physical medicine and rehabilitation and civil hospital karachi. * patients aged ≥60 years. * experienced stress or mixed urinary incontinence symptoms at least 3 times/ week for 3 months or more. exclusion criteria: * have limited mobility (unable to move without crutches, walker, or a cane). * have untreated chronic constipation or have experienced any stool or mucus leakage. * organ prolapse surgery within the last year. * in the last 3 months, any active urinary or vaginal infection. * malignancy

Keywords: urinary incontinence older females pelvic floor disorders urination quality of life
safety study of the switch from oral selexipag to intravenous selexipag in subjects with stable pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: the development of selexipag for intravenous administration will be useful to avoid treatment interruptions in patients with pulmonary arterial hypertension (pah) already treated with selexipag administered orally as tablets (uptravi®). the target population for intravenous selexipag includes those pah patients who are hospitalized and are unable to swallow tablets of uptravi. the primary objective of this study is to assess whether it is safe for patients with pah to temporarily change from selexipag tablets (uptravi®) to selexipag given directly into a vein (intravenous selexipag), and then switching back to the initial oral dose of selexipag.

after screening (visit 1), each subject will participate in the following consecutive treatment periods: period 1(treatment with oral selexipag at visit 2/day 1), period 2 (treatment with intravenous selexipag at visit 2/ day 2 and day 3), period 3 (treatment with oral selexipag starting in the evening of visit 2/day 3 and ending 7 to 11 days later at visit 3). then a safety follow-up period is planned up to end of study visit (eos), which occurs between day 33 and day 40.

Eligibility criteria:
inclusion criteria: * signed informed consent form prior to any study-mandated procedure. * male and female subjects aged from 18 to 75 years (inclusive), * subjects with stable pulmonary arterial hypertension (pah) defined as who functional class i-iii at visit 1 and visit 2, and no change (i.e., introduction or dose change) in pah-specific medication (i.e., era, pde-5 inhibitor or sgc stimulator) and diuretics in the last 28 days prior to visit 2. * subjects currently treated with uptravi® at a stable dose (i.e. unchanged dose) for at least 28 days before visit 2. * women of childbearing potential must have a negative pregnancy test at visit 1 (screening) and visit 2. exclusion criteria: * pregnant, planning to become pregnant or lactating. * known and documented moderate or severe hepatic impairment. * subjects having received gemfibrozil at any time since initiation of uptravi®. * treatment with any prostacyclin and prostacyclin analogs within 28 days prior to visit 1. * sbp \< 90 mmhg at visit 1 or at visit 2. * known or suspected uncontrolled hyperthyroidism. * severe renal failure and ongoing or planned dialysis. * any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results. * known concomitant life-threatening disease with a life expectancy \< 12 months. * treatment with another investigational treatment within 3 months of visit 1.

Keywords: switch intravenous selexipag
predictive value of copeptin in the diagnosis of acute ischemic stroke

Conditions: Cerebral Vascular Accident (CVA)

Summary: in the usa, every year 795,000 patients suffer a cerebral vascular accident (cva), which represents a yearly cost of $73.7 billion. cva is the third main cause of death and the main source of acquired handicap in adults, as a result it is now a key priority in public health and part of " the cva national action plan 2013-2014". copeptin is a polypeptide, by- product of vasopressin metabolism. the increase of copeptin plasma level, as for vasopressin, is connected to hydric balance disorders found in cardio-vascular, renal and endocrine diseases. this link has already shown its interest in the early diagnosis of myocardial infarction and, in a more indirect way, cva. copeptin is associated with acute endogenous stress. it seems to have interesting potential in the diagnosis of cva by its negative predictive value like d-dimeres in pulmonary embolism. proadrenomedullin and brain natriuretic peptide (bnp) are both associated with the prognosis of cardio-vascular diseases and could be interesting in evaluating cva prognosis.


Eligibility criteria:
inclusion criteria: * all patients, male or female, may be included if they meet the following criteria: * patients with suspected ischemic cva admitted in an acute stroke unit (thrombolysis unit). * aged 18 and over. * mri scan undertaken under the current protocol which includes the following sequences: distribution, t2\* (gradient echo), arm, tof and flair. * after information given the consent form is signed: * by the patient .or for those unable to express their consent (in case of coma or severe neurological disorder) by a relative or next of kin. .the patient will be informed as soon as he has recovered his faculties in order to be able to express, if he wishes, his opposition to the pursuit of the research (sample destruction before tested). - the patient must be registered with the social security exclusion criteria: all patients with a contraindication to mri scan: * pacemaker, * implanted cardiac defibrillator, * implanted neuro-stimulator, * cochlear implants * implanted insulin pump * other implanted electronic medical device * vascular intracerebral clip * cardiac valve * other metallic implant * metallic foreign body * ventricular diversion valve * eye or hearing prosthesis * current or suspected pregnancy * breast feeding those who are under protection of justice, under guardianship or curatorship will also be excluded.
primary chemotherapy with adriamycin/cyclophosphamide(ac) vs taxotere/xeloda(tx) for stage ii and iii breast cancer

Conditions: Breast Cancer

Summary: this is an open labeled phase iii randomized trial. the patients with clinical stage ii and iii will undergo mammotome biopsy of breast tumor for histologic diagnosis, immunohistochemical studies for estrogen receptor(er), progesterone receptor(pr), her-2/neu and others. pet results will determine the positivity of lymph node metastasis.

- patients will be randomized to receive regimen a (ac) and regimen b(tx), preoperatively,as follows: regimen a (ac): intravenous infusion of adriamycin 60mg/m2 , over 30 min, ond1 and intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on d1. regimen b(tx): intravenous infusion of taxotere 75 mg/m2 over 1 hr, on d1, and xeloda 1000mg/m2.p.o. bid x 14days on d1-d14 the cycle repeats every 3 weeks for 4 times. premedication for regimen a includes antiemetics, for regimen b, dexamethasone as routinely given. patients who do not respond to the initial two cycles of preoperative chemotherapy will undergo operation. the response rate will be determined by the number of patients with complete and partial responses according to recist guidelines. pathologic complete response is defined as no pathologic evidence of residual disease. safety will be evaluated by the frequency, severity, and relationship of adverse events graded by nci common toxicity criteria(ctc) that occur during the treatment and follow-up periods. time to disease progression will be calculated from the date of study entry to the first objective documentation of progressive disease. response duration will be measured from the date a patient first fulfills the cr or pr criteria to the first date of objective documentation of disease progression. survival time will be calculated from the date of study entry to the date of death

Eligibility criteria:
inclusion criteria: * all patients must have histologically confirmed and newly diagnosed breast cancer: stage ii and iii breast cancer. * pet results will determine node positivity. * no prior hormonal , chemotherapy or radiotherapy is allowed. * no breast operation other than biopsy to make diagnosis is allowed. * age:18-years and older, not pregnant pre-, and postmenopausal women with good performance status (ecog 0-1) * adequate hematopoietic function: 1. absolute granulocyte count \>=1500/mm3, 2. platelet \>=100,000/mm3, hemoglobin \>=10 g/mm3 * adequate renal function: serum creatinine \<=1.5 mg/dl * adequate hepatic function: 1. total bilirubin: \<=1.5 mg/dl 2. ast/alt: \<=three times normal 3. alkaline phosphatase: \<=three times normal * adequate cardiac function: normal or nonspecific ekg taken within 1 mo of enrollment exclusion criteria: * patients who received hormonal , chemotherapy or radiotherapy for breast cancer * patients who underwent surgery for breast cancer * patients who have history of cancer other than in situ uterine cervix cancer or nonmelanotic skin cancer

Keywords: primary
study of the resvent rxibreeze™ pap system to treat obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the goal of this clinical trial is to test the automatic positive airway pressure (apap) function of the rxibreeze pap system in adult subjects with obstructive sleep apnea (osa). the main questions the study aims to answer are: 1. is apnea-hypopnea index (ahi) detection using the rxibreeze pap system equivalent to apnea-hypopnea index (ahi) detection using psg? 2. what is the responder rate using the rxibreeze pap system? participants will use the apap function of the rxibreeze pap system while undergoing polysomnography (psg) for two separate nights in a sleep center. during each visit, participants will also complete two patient reported outcome questionnaires: * epworth sleepiness score (ess); and * functional outcomes of sleep questionnaire (fosq) short form.

this is a prospective, multicenter, single-arm trial designed to evaluate the safety and effectiveness of the rxibreeze pap system to treat obstructive sleep apnea and detect breathing events. eligible subjects who meet all inclusion criteria and none of the exclusion criteria will be consented for study participation. the study will enroll up to 68 subjects. baseline psg will be obtained. subjects will return to the sleep lab and use the rxibreeze pap system while undergoing a psg. the data from both the rxibreeze pap system and psg from both nights will be sent to an independent core lab for blinded ahi scoring. data will be evaluated in accordance with current american academy of sleep medicine (aasm) scoring guidelines. in addition to the device/psg data scoring, subjects will complete the epworth sleepiness score (ess) and the functional outcomes of sleep questionnaire (fosq) short form (10 questions) and be assessed for device- and/or therapy-related adverse events (aes) at the end of each visit.

Eligibility criteria:
inclusion criteria: 1. subject is ≥ 22 years old 2. subject has been diagnosed with osa (as scored per aasm scoring guidelines) and has an ahi ≥ 10, based on the results of a sleep study conducted at an accredited sleep lab, within 30 days prior to enrollment 3. subject weighs \>30 kg 4. subject has been prescribed the use of an auto cpap system 5. subject agrees to fulfill all study-required tests, sleep lab session attendance, and assessments 6. subject agrees to use the rxibreeze pap system as prescribed 7. subject is willing and able to provide informed consent exclusion criteria: 1. subject has been diagnosed with a sleep disorder other than osa 2. subject's central apnea index from the baseline psg is \> 20% of ahi 3. subject has been diagnosed with severe (stage 3) coronary artery disease 4. subject has been diagnosed with bullous lung disease 5. subject has been diagnosed with hypotension 6. subject has been diagnosed with bypassed upper airway pneumothorax 7. subject is pregnant, breastfeeding, or planning on becoming pregnant during trial participation 8. subject, in the opinion of the investigator, is not suitable for trial participation

Keywords: obstructive sleep apnea sleep apnea cpap pap apap